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BRIEF REPORT: CLINICAL SCIENCE
Food Insufficiency Is AssociatedWith Lack of Sustained Viral
Suppression Among HIV-Infected Pregnant and
Breastfeeding Ugandan Women
Catherine A. Koss, MD,*† Paul Natureeba, MBChB,† Dorcas Nyafwono,† Albert Plenty, MSPH,†‡
Julia Mwesigwa, MBChB, MSc,†§ Bridget Nzarubara, MBChB, MSc,† Tamara D. Clark, MHS,*†
Theodore D. Ruel, MD,†k Jane Achan, MBChB, MMed, PhD,†§ Edwin D. Charlebois, MPH, PhD,†‡
Deborah Cohan, MD, MPH,†¶ Moses R. Kamya, MBChB, MMed, MPH, PhD,†# Diane V. Havlir, MD,*†
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Abstract: Food insecurity is associated with poor virologic
outcomes, but this has not been studied during pregnancy and
breastfeeding. We assessed sustained viral suppression from 8 weeks
on antiretroviral therapy to 48 weeks postpartum among 171
pregnant and breastfeeding Ugandan women; 74.9% experienced
food insufficiency. In multivariable analysis, food insufficiency
[adjusted odds ratio (aOR) 0.38, 95% confidence interval (CI): 0.16
to 0.91], higher pretreatment HIV-1 RNA (aOR 0.55 per 10-fold
increase, 95% CI: 0.37 to 0.82), and lopinavir/ritonavir versus
efavirenz (aOR 0.49, 95% CI: 0.24 to 0.96) were associated with
lower odds of sustained viral suppression. Interventions to address
food security may improve virologic outcomes among HIV-
infected women.
Key Words: food insecurity, nutrition, perinatal transmission,
pregnancy, household hunger, virologic outcomes
(J Acquir Immune Defic Syndr 2016;71:310–315)
INTRODUCTION
Food insecurity, defined as uncertain access to safe and
nutritious foods,1 and food insufficiency (FI), in which
inadequate quantities of food are available,2–4 have been
associated with poor health outcomes in HIV-infected pop-
ulations, including reduced adherence to antiretroviral therapy
(ART) and mortality.5–7 Moreover, food insecurity has been
associated with lower rates of viral suppression among HIV-
infected adults in the United States8–10 and rural Uganda.11
Pregnant and breastfeeding women may be particularly
vulnerable to food insecurity and insufficiency because of
increased nutritional demands12,13 at a time of reduced physical
ability to generate income and obtain and prepare food.14 Poor
nutritional status and food insecurity have been associated with
adverse pregnancy outcomes among HIV-infected women and
reduced uptake of interventions to prevent perinatal trans-
mission.15–19 Among pregnant women treated with combina-
tion ART, food insecurity has been associated with reduced
pharmacokinetic exposure to antiretrovirals (ARVs), inade-
quate maternal weight gain during pregnancy, low birth
weight, and preterm delivery.20–22 Furthermore, food insecurity
may also be a barrier to exclusive breastfeeding.23,24
World Health Organization guidelines now recommend
that all pregnant and breastfeeding HIV-infected women
initiate combination ART and encourage lifelong therapy.25
Achieving and maintaining viral suppression during preg-
nancy and breastfeeding will be critical to attaining the dual
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goals of preserving maternal health and eliminating perinatal
HIV infections. Viral suppression, in turn, is dependent on
adequate ARV adherence and pharmacokinetic exposure, both
of which may be influenced by insufficient food intake.6,7,20,26–28
Although food insecurity and insufficiency may be
major drivers of virologic outcomes among childbearing
HIV-infected women in resource-limited settings, this
relationship has not yet been examined. In Uganda, where
the prevalence of HIV is 7.3%29 and 48% of households are
food energy deficient,30 food security and sufficiency may
impact HIV outcomes. Therefore, we examined the associ-
ation between household FI and viral suppression during
pregnancy and breastfeeding in a cohort of HIV-infected
women in rural Uganda.
METHODS
Study Design and Population
We performed a secondary analysis of data from
the PROMOTE-Pregnant Women and Infants study
(NCT00993031), which was designed to test the hypothesis
that lopinavir/ritonavir would reduce the prevalence of placental
malaria. Study procedures31 and results20–22,24,31–35 are described
elsewhere. Briefly, the study enrolled HIV-infected, ART-naive
pregnant women between 12 and 28 weeks gestation in Tororo,
Uganda from December 2009 to September 2012. Women
initiated ART at enrollment and were randomized to receive
lopinavir/ritonavir or efavirenz, in combination with lamivudine/
zidovudine. Participants received multivitamins containing iron
and folic acid, iron supplements, mebendazole, and trimetho-
prim/sulfamethoxazole prophylaxis. Women were seen at the
study clinic every 4 weeks; participants continued ART and
were followed for up to 1 year postpartum. Women were
counseled to breastfeed their infants for 1 year, with exclusive
breastfeeding for the first 6 months of life. One participant
switched from lopinavir/ritonavir to efavirenz because of the
need for tuberculosis treatment; all other participants remained
on their assigned study drug.
This analysis includes women who participated in
assessments of food security, which were performed among
all participants actively enrolled from September 11, 2011, to
February 4, 2012. The study protocol was approved by the
Makerere University School of Medicine Research and Ethics
Committee, the Uganda National Council for Science and
Technology, Cornell University Institutional Review Board,
and the University of California, San Francisco Committee on
Human Research. Participants provided written informed
consent in their preferred language.
Measurements
HIV-1 RNA was measured at screening, 8 weeks after
ART initiation, delivery, 8, 24, and 48 weeks postpartum, and
at other intervals for clinical management. HIV-1 RNA
polymerase chain reaction testing was performed using
COBAS AMPLICOR version 1.5 (Roche Molecular Diag-
nostics, Pleasanton, CA) until September 2012, and thereafter
with the m2000 RealTime HIV-1 assay (Abbott Laboratories,
Abbott Park, IL). The primary outcome for this analysis was
sustained viral suppression from 8 weeks after ART initiation
to 48 weeks postpartum. Viral suppression was dichotomized
as “sustained” if HIV-1 RNA #400 copies per milliliter (the
lower limit of detection of the assays) at all measured time
points and “not sustained” if HIV-1 RNA .400 copies per
milliliter at any measured time point. Sixteen participants had
missing HIV-1 RNA measurements at 8 weeks on ART (N = 8)
or 48 weeks postpartum (N = 8).
FI was operationalized using the Household Hunger Scale
(HHS),36 a subset of 3 questions about insufficient food
quantities from the 9-item Household Food Insecurity Access
Scale,37 which has been previously been validated for cross-
cultural use38 and measured among HIV-infected adults in rural
Uganda.28,39 The HHS asks the frequency over the previous 4
weeks of (1) having no food to eat of any kind in one’s
household, (2) going to sleep at night hungry, and (3) going
a whole day and whole night without eating. A response of
“never” received 0 points, “rarely or sometimes” received 1
point, and “often” received 2 points; points were summed as
a score, with a maximum score of 6 points for a response of
“often” to all 3 questions. For logistic regression analyses, FI was
dichotomized as no household hunger (HH) versus any HH (any
positive response, indicating the presence of FI). FI was assessed
once, in the season when food is most abundant in Tororo, such
that FI scores would be the most conservative and have the least
seasonal variation. FI interviews were conducted among 197
women, at a median of 5.6 months postpartum (interquartile
range 2.2–9.2); 18 participants were interviewed before delivery.
A household wealth index was generated by performing
a principal component analysis of questions regarding house-
hold possession of assets, including a radio, telephone,
television, motorcycle, or bicycle, among all PROMOTE
participants.22 The first principal component was used to create
the index. Tertiles of the wealth index were used to categorize
individual household wealth relative to the cohort. Participants
in the middle and highest tertiles of wealth were grouped
together for comparison with those in the lowest wealth tertile.
Residence within the town of Tororo was defined as urban
based on GPS coordinates; other residences in Tororo district
were classified as rural. Gestational age at enrollment was
determined based on last menstrual period and fetal ultra-
sound.21 For calculation of body mass index (BMI), maternal
height was measured using a wall-mounted measuring tape
(Seca 206; Seca, Hamburg, Germany); maternal weight was
measured using a Seca 876 mechanical scale until September
2011 and thereafter using a Seca 874 digital scale. Participants
were asked whether they were breastfeeding every 4 weeks
postpartum. The end of breastfeeding was defined as the last
period in which a participant reported any breastfeeding
(exclusive or partial). ART adherence was assessed by self-
reported recall of the number of pills taken of the expected
number of pills over the 3 days before each study visit.
Statistical Analysis
Characteristics of enrolled participants with and without
FI were compared using the x2 test or Fisher’s exact test for
categorical variables and the Wilcoxon rank-sum test for
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continuous variables. The proportion of participants with and
without FI who achieved viral suppression at individual time
points was evaluated using Fisher’s exact test because of the
small number of participants who did not achieve viral
suppression at each time point. A 4-week measurement
window was used for virologic outcomes.
Logistic regression models were used to evaluate the
association between sustained viral suppression, FI, and cova-
riates in our causal model (see Figure S1, Supplemental Digital
Content, http://links.lww.com/QAI/A755). We postulated that
the association between FI and sustained viral suppression is
mediated through effects on adherence, absorption/pharmacoki-
netics/bioavailability, BMI, depression, poor nutrition, and
reduced protein binding of drug. ART regimen and pretreatment
HIV-1 RNA were included in the multivariable model as
independent predictors of sustained viral suppression. House-
hold wealth was included in the model as a confounder of the
relationship between FI and viral suppression. Age was
evaluated as a potential confounder. Using the causal model
as a guide, we evaluated the effect of individual predictors and
confounders, and assessed overall model fit to achieve the final
model. Inclusion of age in the multivariable model did not alter
the association between FI and viral suppression and did not
improve overall model fit; thus, age was excluded from the final
model. Statistical analyses were performed using SAS software
version 9.3 (SAS Institute, Cary, NC).
RESULTS
Participant Characteristics by Food
Insufficiency Status
Of 197 women in the PROMOTE study who underwent
FI assessment, 26 were excluded from this analysis: 2 did not
deliver, 8 were withdrawn before 48 weeks postpartum, and 16
had missing HIV-1 RNA measurements. There were no
statistically significant differences between included and
excluded participants in any predictor variables, including FI
status and pretreatment HIV-1 RNA, and viral suppression at
delivery. Among 171 participants, 43 (25.1%) reported no FI
(score 0) and 128 (74.9%) reported FI (any HH) (Table 1). Of
128 participants with FI, 12 (9.4%) reported severe HH (score
4–6), 70 (54.7%) reported moderate HH (score 2–3), and 46
(35.9%) had little HH (score 1). At baseline, characteristics
were similar between participants with and without FI,
including maternal age, gestational age, CD4 cell count, and
log10 HIV-1 RNA. At 24 weeks postpartum, 99.2% of food
insufficient participants and 100% of food sufficient participants
were breastfeeding their infants; 68.6% (food insufficient) and
80.5% (food sufficient) reported exclusive breastfeeding. At 48
weeks postpartum, 91.7% of food insufficient participants and
95.1% of food-sufficient participants reported partial breast-
feeding. Two infants acquired HIV; both of their mothers
reported FI (one moderate and one severe HH).
Virologic Outcomes
Overall, a high proportion of participants achieved viral
suppression at individual time points throughout the study
TABLE 1. Characteristics of 171 HIV-Infected Pregnant
Women in the PROMOTE Trial at Enrollment and During Study
Follow-Up, by Food Insufficiency Status
Characteristics
Food Insufficiency
Any (N = 128) None (N = 43)
Enrollment
Age, mean (SD), yrs 29.4 (5.6) 29.3 (5.3)
Education completed, n (%)
Less than primary 14 (10.9) 8 (18.6)
Primary or higher 114 (89.1) 35 (81.4)
Household wealth, n (%)
Lowest 50 (39.7) 11 (25.6)
Middle/highest 76 (60.3) 32 (74.4)
Urban residence (versus rural), n (%) 20 (16.0) 10 (24.4)
No. previous pregnancies, n (%)
0 9 (7.0) 5 (9.8)
1–2 29 (22.7) 11 (25.6)
3 or more 90 (70.3) 27 (62.8)
No. living children, median (IQR) 3.0 (1.5–4.0) 3.0 (1.0–5.0)
Gestational age, median (IQR), wk 20.1 (17.7–24.5) 22.1 (17.4–24.4)
BMI, median (IQR), kg/m2 21.1 (19.9–22.9) 21.9 (20.4–24.1)
HIV diagnosed in current
pregnancy, n (%)
54 (42.2) 17 (39.6)
WHO stage 1, n (%) 123 (96.1) 42 (97.7)
CD4 cell count, median (IQR),
cells/mm3
386 (271–487) 423 (261–559)
Pretreatment HIV-1 RNA, median
(IQR), log10 copies/mL
4.3 (3.4–4.9) 4.2 (3.5–4.8)
During Study Follow-Up
Efavirenz-based ART regimen
(versus lopinavir/ritonavir), n (%)
68 (53.1) 18 (41.9)
Self-reported ART adherence, mean
(SD), %
During pregnancy 97.2 (8.8) 99.1 (3.0)
During breastfeeding 99.2 (2.4) 99.6 (1.5)
During pregnancy and
breastfeeding
98.8 (2.5) 99.5 (1.6)
Grade 1 or 2 nausea or vomiting
during pregnancy or
breastfeeding, n (%)
45 (35.2) 14 (32.6)
Grade 1 or 2 diarrhea during
pregnancy or breastfeeding, n (%)
64 (50.0) 13 (30.2)*
Breastfeeding, n/N (%)
24 wk postpartum, partial or
exclusive
119/120 (99.2) 41/41 (100)
24 wk postpartum, exclusive 83/121 (68.6) 33/41 (80.5)
48 wk postpartum, partial 110/120 (91.7) 39/41 (95.1)
Viral suppression, n/N (%)
8 wk after ART initiation 111/128 (86.9) 42/43 (97.7)
Delivery 109/121 (90.1) 37/40 (92.5)
8 wk postpartum 110/124 (88.7) 36/40 (90.0)
24 wk postpartum 101/116 (87.1) 40/40 (100)
48 wk postpartum 112/128 (87.5) 41/43 (95.4)
Sustained viral suppression, n/N (%)† 77/128 (60.2) 34/43 (79.1)‡
*P = 0.02.
†At all measured time points from 8 weeks after ART initiation to 48 weeks
postpartum.
‡P = 0.03.
IQR, interquartile range; WHO, World Health Organization.
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(Table 1); 90.1% of food insufficient women and 92.5% of
food sufficient women were virologically suppressed at
delivery. A total of 77 women (60.2%) with FI achieved
sustained viral suppression, compared with 79.1% of women
reporting no FI (P = 0.03). The proportion of participants who
achieved sustained viral suppression by HH status was 34 of
43 (79.1%, no HH), 29 of 46 (63%, little HH), 39 of 70
(55.7%, moderate HH), and 9 of 12 (75%, severe HH).
In a multivariable model of sustained viral suppression,
FI [adjusted odds ratio (aOR) 0.38, 95% confidence interval
(CI): 0.16 to 0.91, P = 0.03], pretreatment HIV-1 RNA (aOR
0.55 per 10-fold increase, 95% CI: 0.37 to 0.82, P , 0.01),
and ART regimen of lopinavir/ritonavir versus efavirenz
(aOR 0.49, 95% CI: 0.24 to 0.96, P = 0.04) were associated
with lower odds of viral suppression (Table 2).
DISCUSSION
In this cohort of HIV-infected women in rural Uganda
who initiated ART during pregnancy, FI was highly preva-
lent, consistent with previous estimates among nonpregnant
HIV-infected Ugandan adults.11 Although the proportion of
women who achieved viral suppression was high overall in
this cohort, with more than 90% virologically suppressed at
delivery,33 FI was associated with 62% lower odds of
achieving and sustaining viral suppression during pregnancy
and breastfeeding. To our knowledge, this is the first study to
evaluate the association between FI and virologic outcomes
during pregnancy and breastfeeding, when viral suppression
has implications both for preserving maternal health and
reducing the risk of perinatal transmission. Thus, in this
cohort of women with high median CD4 cell count, the strong
association between FI and lack of sustained viral suppression
suggests that FI may be an important and modifiable risk
factor for virologic failure.
The results of this study are consistent with previously
published reports of poor virologic outcomes among non-
pregnant food insecure individuals in the United States and
Uganda, in whom food insecurity was associated with 40%–
77% lower odds of viral suppression.8–11 The consistency of
these findings across diverse settings and the modifiable
nature of food insecurity underscore the need to understand
the mechanisms by which FI and food insecurity may lead to
virologic failure, such that appropriate interventions can be
implemented. Potential causal pathways include behavioral7
(eg, decreased adherence due to lack of food with which to
take medicines, competing resource demands precluding
access to medicines), psychological6,40 (eg, depression and
anxiety associated with FI, leading to decreased adherence),
and pharmacokinetic alterations26 (eg, altered ARV absorp-
tion and reduced bioavailability in food insecure individuals).
Nutritional supplements, ready to use supplementary
foods, and other strategies may reduce FI and are increasingly
being studied and implemented programmatically in non-
pregnant HIV-infected populations.41–43 In a pilot study in
Zambia, food supplementation led to increased ART adher-
ence.44 Similarly, food supplementation was associated with
improved clinic attendance, BMI, and food security in Haiti.45
Another study in Haiti that randomized nonpregnant HIV-
infected adults on ART to ready to use supplementary foods or
a corn-soy blend supplement found similar improvements in
CD4 cell count, ART adherence, and household wealth index
in each arm.46 Nonetheless, the optimal components, quantity,
and duration of supplementation are not yet known.43,47,48
Whereas several studies have addressed micronutrient
(vitamin/mineral) supplementation among HIV-infected preg-
nant women,49 few studies of macronutrient (carbohydrate/
protein/fat) supplementation have been conducted in this
population, such that little is known about the impact on viral
suppression. A trial in Malawi found that a lipid-based
nutrient supplement plus maize reduced weight loss during
breastfeeding among HIV-infected women compared with
those receiving a maize provision alone, but did not affect
infant weight gain.50,51 The first study of macronutrient
supplementation among HIV-infected pregnant women (a
subgroup of PROMOTE participants not included in this
analysis) found that a lipid-based nutrient supplement and
instant soy porridge were highly acceptable.48
This study has several important strengths, including
being the first to investigate the role of FI in virologic
outcomes among pregnant and lactating women and the
repeated measures of HIV-1 RNA. A limitation of this study
TABLE 2. Factors Associated With Sustained Viral Suppression From 8 Weeks After ART Initiation to 48 Weeks Postpartum, Among
171 HIV-Infected Pregnant and Breastfeeding Women in the PROMOTE Trial
Variable Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Food insufficiency
Any household hunger versus none 0.40 (0.18 to 0.90) 0.03 0.38 (0.16 to 0.91) 0.03
Pretreatment HIV-1 RNA
Per 10-fold increase 0.55 (0.38 to 0.82) ,0.01 0.55 (0.37 to 0.82) ,0.01
ART regimen
Lopinavir/ritonavir versus efavirenz 0.59 (0.31 to 1.11) 0.10 0.49 (0.24 to 0.96) 0.04
Household wealth
Lowest versus middle/highest 0.69 (0.36 to 1.32) 0.26 0.76 (0.38 to 1.53) 0.45
Age
Per year 1.06 (1.00 to 1.12) 0.06
OR, odds ratio.
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is that FI was measured only once, and the HHS only assessed
experiences in the 4 weeks before FI interviews. In addition,
FI was generally not measured at the beginning of the period
during which virologic outcomes were measured. Thus, it is
possible that variation in FI occurred throughout the study
period that we were unable to measure. Repeated measure-
ments of FI would have provided stronger evidence of
causality. However, because FI was measured in the season
of greatest food security (ie, when FI is lowest in Tororo), the
strength of the relationship between FI and viral suppression
may be underestimated. Participants received resources that are
protective against some of the potential pathways by which FI
may be deleterious (ie, reimbursement for transportation to the
study clinic, free provision of ART and medical care); this may
have also attenuated the strength of the observed association
between FI and virologic outcomes. In addition, we do not
have data on quantity or quality of diet.
In summary, FI may be an important and modifiable
determinant of adverse virologic outcomes among pregnant
and lactating women. As millions of HIV-infected women
worldwide initiate and continue ART during pregnancy and
breastfeeding, there is a pressing need to address barriers to
achieving and maintaining viral suppression. Interventions to
reduce FI may result in improved health outcomes among
HIV-infected women and their children and merit further
attention from the research and programmatic communities.
Future research should elucidate the mechanisms driving this
association, such that efficacious and cost-effective interven-
tions can be implemented.
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